Skip to content
CancerIndex

Publication

Inhibiting calreticulin palmitoylation enhances the efficacy of elesclomol-CuCl2 on oxaliplatin-triggered immunogenic cell death in pancreatic cancer.

Zhimiao Zou, Xia Li, Yan Ma, Yiyun Huang, Qiangwei Jiang, Yuqin Xu, Sai Zhao, Wenkai Ye, Qiao Ke, Jiashuo Chao, Liuqi Wang, Jiantao Huang, Dan Sun, Yuhua Zhang

Pharmacological researchSep 15, 2026PMID 42744192doi:10.1016/j.phrs.2026.108459 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Immunogenic cell death (ICD) is a robust strategy to reprogram immunologically "cold" pancreatic ductal adenocarcinoma (PDAC) into "hot" tumors and augment immunotherapeutic efficacy, yet clinically viable ICD-inducing regimens and their regulatory mechanisms remain elusive. Here, we sought to…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.